BioCardia Inc Share Price Today: Live Updates & Key Insights

BioCardia Inc share price today is $0.851, up -6.07%. The stock opened at $0.8701 against the previous close of $0.905, with an intraday high of $0.8701 and low of $0.85.

BioCardia Inc Share Price Chart

BioCardia Inc

us-stock
To Invest in {{usstockname}}
us-stock

BioCardia Inc Share Price Performance

$0.851 -0.0607(-6.07%) BCDA at 27 Jul 2026 02:08 PM Biotechnology
Lowest Today 0.85
Highest Today 0.8701
Today’s Open 0.8701
Prev. Close 0.905
52 Week High 2.38
52 Week Low 0.78
Day’s Range: Low 0.85 High 0.8701
52-Week Range: Low 0.78 High 2.38
1 day return -
1 Week return -2.3
1 month return -28.62
3 month return -26.47
6 month return -36.35
1 year return -63.39
3 year return -94.31
5 year return -98.32
10 year return -

BioCardia Inc Institutional Holdings

Vanguard Group Inc 0.91

CM Management, LLC 0.87

Vanguard Capital Management, LLC 0.84

Geode Capital Management, LLC 0.63

Vanguard Institutional Extnd Mkt Idx Tr 0.46

Vanguard Fiduciary Trust Co 0.45

Citadel Advisors Llc 0.43

Fidelity Extended Market Index 0.40

Vanguard Total Stock Mkt Idx Inv 0.37

Abante Quant Value FI 0.26

Susquehanna International Group, LLP 0.26

Pingora Partners LLC 0.24

Brown Advisory Holdings Inc 0.24

XTX Topco Ltd 0.16

Virtu Financial LLC 0.14

Commonwealth Equity Services, LLC 0.12

TWO SIGMA SECURITIES, LLC 0.10

Renaissance Technologies Corp 0.09

Spartan Extended Market Index Pool F 0.09

Fidelity Series Total Market Index 0.07

NT Ext Equity Mkt Index Fund - NL 0.06

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.04

Spartan Total Market Index Pool G 0.04

Fidelity Total Market Index 0.02

Morgan Stanley - Brokerage Accounts 0.02

Tower Research Capital LLC 0.02

Allied Private Wealth LLC 0.01

Fidelity Nasdaq Composite Index 0.01

Northern Trust Extended Eq Market Idx 0.00

NT Ext Equity Mkt Index Fund - Lending 0.00

Global Retirement Partners, LLC. 0.00

NT Ext Eq Mkt Idx Fd DC Lending Tier 5 0.00

Vanguard Global Advisers, LLC 0.00

Vanguard U.S. Eq Idx £ Acc 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Blackstone Alternative Multi-Strategy I 0.00

Northern Trust Wilshire 5000 0.00

NT US Market Cap Index Fund - Ld 0.00

SSgA U.S. Total Market Index Strategy 0.00

SBI Securities Co Ltd 0.00

BioCardia Inc Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

BioCardia Inc Fundamentals

Market Cap 13.47 M

PB Ratio 12.3461

PE Ratio 0.0

Enterprise Value 13.15 M

Total Assets 3.41 M

Volume 129816

BioCardia Inc Company Financials

Annual Revenue FY23:477000 0.5M, FY22:1352000 1.4M, FY21:1015000 1.0M, FY20:145000 0.1M, FY19:710000 0.7M

Annual Profit FY23:66000 0.1M, FY22:-10549000 -10.5M, FY21:1015000 1.0M, FY20:141000 0.1M, FY19:352000 0.4M

Annual Net worth FY23:-11571000 -11.6M, FY22:-11913000 -11.9M, FY21:-12621000 -12.6M, FY20:-15005000 -15.0M, FY19:-14819000 -14.8M

Quarterly Revenue Q1/2026:0 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q1/2026:-124000 -0.1M, Q3/2025:-107000 -0.1M, Q2/2025:-1368000 -1.4M, Q1/2025:-1530000 -1.5M, Q3/2024:null 0.0M

Quarterly Net worth Q1/2026:-2259000 -2.3M, Q3/2025:-1483000 -1.5M, Q2/2025:-2049000 -2.0M, Q1/2025:-2712000 -2.7M, Q3/2024:-1737000 -1.7M

About BioCardia Inc & investment objective

Company Information BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.

Organisation Biotechnology

Employees 17

Industry Biotechnology

CEO Dr. Peter A. Altman Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

BioCardia Inc FAQs

What is the share price of BioCardia Inc today?

The current share price of BioCardia Inc is $0.851.

Can I buy BioCardia Inc shares in India?

Yes, Indian investors can buy BioCardia Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy BioCardia Inc shares in India?

You can easily invest in BioCardia Inc shares from India by:

Can I buy fractional shares of BioCardia Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of BioCardia Inc?

BioCardia Inc has a market cap of $13.47 M.

In which sector does BioCardia Inc belong?

BioCardia Inc operates in the Biotechnology sector.

What documents are required to invest in BioCardia Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of BioCardia Inc?

The PE ratio of BioCardia Inc is N/A and the PB ratio is 12.35.